Generation of “Off-the-Shelf” Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells

Jieming Zeng, 1,* Shin Yi Tang, 1,2 Lai Ling Toh, 1 and Shu Wang 1,2,*

1Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, #09-01, Singapore 138669, Singapore
2Department of Biological Sciences, National University of Singapore, Singapore 117543, Singapore

*Correspondence: jmezeng@ibn.a-star.edu.sg (J.Z.), swang@ibn.a-star.edu.sg (S.W.)
https://doi.org/10.1016/j.stemcr.2017.10.020

SUMMARY

Current donor cell-dependent strategies can only produce limited “made-to-order” therapeutic natural killer (NK) cells for limited patients. To provide unlimited “off-the-shelf” NK cells that serve many recipients, we designed and demonstrated a holistic manufacturing scheme to mass-produce NK cells from induced pluripotent stem cells (iPSCs). Starting with a highly accessible human cell source, peripheral blood cells (PBCs), we derived a good manufacturing practice-compatible iPSC source, PBC-derived iPSCs (PBC-iPSCs) for this purpose. Through our original protocol that excludes CD34+ cell enrichment and spin embryoid body formation, high-purity functional and expandable NK cells were generated from PBC-iPSCs. Above all, most of these NK cells expressed no killer cell immunoglobulin-like receptors (KIRs), which renders them unrestricted by recipients’ human leukocyte antigen genotypes. Hence, we have established a practical “from blood cell to stem cells and back with less (less KIRs)” strategy to generate abundant “universal” NK cells from PBC-iPSCs for a wide range of patients.

INTRODUCTION

Natural killer (NK) cells are innate lymphocytes that kill malignant cells and virus-infected cells (Domogala et al., 2015; Miller, 2013). Target recognition and activation of NK cells depend on an array of activating receptors and inhibitory receptors, which entirely differ from the major histocompatibility complex-restricted T cell receptor (TCR)-dependent mechanism of T cells (Moretta et al., 2014). Thus, it is feasible to use allogeneic NK cells to treat cancers without causing graft-versus-host diseases (GVHDs) (Leung, 2014; Lim et al., 2015), and this effectively expands the cell sources for NK cell therapy beyond an autologous one.

In current clinical trials, large dosages of NK cells ranging from $5 \times 10^6$ to $5 \times 10^7$/kg body weight have been used (Lapteva et al., 2014). One typical approach to generate such large amounts of allogeneic NK cells is enrichment of NK cells from donor-derived leukapheresis products. Different protocols have been established to make NK cell products through immunomagnetic depletion of T and B cells and selection of CD56+ cells (Koehl et al., 2013). Since residual T and B cells may cause GVHDs and passenger B lymphocyte-mediated complications, respectively, purities of such products are especially crucial for their applications in allogeneic settings. However, to generate high-purity NK cell products, a prolonged manufacturing process is necessary, which not only compromises recovery of NK cells but also their viability and potency. With a low recovery rate, obtaining sufficient NK cells from a single leukapheresis product is difficult, not to mention the limited availability of donor-derived leukapheresis products. Another popular approach to make NK cell products is expansion of NK cells from peripheral blood mononuclear cells (PBMCs) using feeder cells, such as K562 cells modified with membrane-bound molecules such as interleukin-15 (IL-15) and 4-1BB ligand (K562-mbIL15-41BBL) (Fujisaki et al., 2009). These feeder cells can rapidly expand NK cells from PBMCs by 21.6-fold in 7 days (Fujisaki et al., 2009), or from cryopreserved apheresis products by 70-fold in 8 days (Lapteva et al., 2014). Yet, the purities of such short-term cultured NK cells are about 60%–70%, and further expansion up to 21 days or enrichment of NK cells is still required to achieve the purities needed for allogeneic use (Fujisaki et al., 2009; Lapteva et al., 2014). Although the above-mentioned approaches are currently being used to generate NK cell products, the scalabilities of such manufacturing strategies are poor. Like any other donor cell-dependent manufacturing processes, generating NK cell products from primary cells of various donors is difficult to be standardized due to the variable starting materials. It demands specialized facilities and skills, complicated logistics, and high operation cost, which limit the availability of NK cell therapy to a few particular agencies.

Along with the difficulties during manufacturing, selecting a suitable donor of NK cells for a particular patient to improve clinical outcome is another hurdle faced by current strategies for NK cell production (Benson and Caligiuri, 2014; Leung, 2014; Thielens et al., 2012). NK cells express clonally distributed inhibitory receptors known as killer cell immunoglobulin-like receptors (KIRs) (Parham, 2005; Thielens et al., 2012). Each individual KIR recognizes a specific human leukocyte antigen (HLA) class I molecule known as KIR ligand, e.g., KIR2DL1 binds HLA-C2,
KIR2DL2 and KIR2DL3 bind HLA-C1, KIR3DL1 binds HLA-Bw4, and KIR3DL2 binds HLA-A3 and HLA-A11 (Thielen et al., 2012). Binding of KIR ligands to inhibitory KIRs suppresses cytotoxicity of NK cells. To alleviate such inhibition on NK cells and thus to enhance their cytotoxicity against a patient’s cancer cells, elaborately selecting an NK cell donor for that particular patient to obtain a KIR-HLA mismatch in an anti-cancer direction is critical (Benson and Caligurì, 2014; Leung, 2014; Murphy et al., 2012; Thielen et al., 2012). This selection is based on donor KIR typing and recipient HLA typing. A donor is suitable if an inhibitory KIR is present in the donor but the KIR ligand is absent in the recipient (Leung, 2014). The involvement of both KIR and HLA, two highly diverse gene families in human immune system, decides that current donor cell-dependent manufacturing platforms can only produce “custom-made” NK cell products for limited patients instead of “off-the-shelf” ones for a wide range of patients. Therefore, it is imperative to explore an alternative manufacturing strategy that circumvents these aforementioned issues.

In the age of pluripotency, human pluripotent stem cells (hPSCs), especially induced pluripotent stem cells (iPSCs), have emerged as a reliable and standardizable starting material to produce immune cells such as dendritic cells (Zeng et al., 2012, 2015; Zeng and Wang, 2014) and NK cells (Knorr et al., 2013; Woll et al., 2005, 2009). Although a couple of studies have shown the generation of NK cells from hPSCs, these existing protocols require procedures that are unsuitable for large-scale production, e.g., enriching CD34+ cells (Woll et al., 2005, 2009), forming spin embryoid bodies (EBs) (Knorr et al., 2013) and heavily relying on long-term NK cell expansion that lasts more than 2 months (Knorr et al., 2013). Moreover, using these current methods, the resulting NK cells express high-level KIRs (Knorr et al., 2013; Woll et al., 2005, 2009), which restrict their applications to recipients of certain HLA typing. Up to now, a robust good manufacturing practice (GMP)-compatible protocol that consistently generates NK cells from various sources of hPSCs is yet to be reported. To facilitate and contribute to the development of a GMP-ready protocol in the future, we designed and demonstrated a holistic manufacturing scheme to mass-produce NK cells from hPSCs. Starting with a highly accessible human cell source, peripheral blood cells (PBCs), we generated a GMP-compatible hPSC source, PBC-derived iPSCs (PBC-iPSCs) to produce NK cells. Through our original protocol that excludes CD34+ cell enrichment and spin EB formation, high-purity functional and expandable NK cells were generated from PBC-iPSCs. Above all, most of these PBC-iPSC-derived NK (PBC-iPSC-NK) cells expressed no KIRs, which renders them unrestricted by recipients’ HLA genotypes. These “HLA-unrestricted” NK cells may serve as a universal “off-the-shelf” NK cell source for many recipients.

**RESULTS**

**Generation of NK Cells from hPSCs**

To establish a robust and practical protocol for NK cell production from hPSCs (Figure 1A), we started with a classical hPSC source, the widely used human embryonic stem cell (hESC) line, H1 (Figure 1B). In stage one of this two-stage protocol, to induce hematopoietic differentiation, H1 cells were co-cultured with overgrown OP9 cells, a bone marrow stromal cell line (Figure 1A). On day 12 of co-culture, many differentiated colonies appeared (Figure 1C), and small populations of CD34+ cells (Figure 1J) were consistently observed. In stage two, to induce lymphoid commitment, the differentiated cells were harvested and co-cultured with OP9-DLL1 cells, a modified OP9 cell line expressing Notch ligand Delta-like-1 (DLL1), on a weekly basis in the presence of stem cell factor (SCF), Fms-related tyrosine kinase 3 ligand (FLT3L), and IL-7 (Figure 1A). Seven days after first co-culture with OP9-DLL1 (day 19), most differentiated cells still grew as adherent cells (Figure 1D); after second co-culture (day 26), some bright, round, and semi-attached cells started to pop out (Figure 1E); after third co-culture (day 33) these cells detached and assembled in the center of culture plate well (Figures 1F and 1G); after fourth co-culture (day 40), more suspension cells appeared (Figures 1H and 1I). Morphologically, these suspension cells were small, round, and bright lymphoid cells (Figures 1G and 1I); phenotypically, they appeared as a defined population on scatter plots (Figures 1K and 1L); most were CD45+ CD56+, but CD3~TCRab~CD4~CD8~ (Figures 1K and 1L), which is typical for NK cells. Thus, by going through hematopoietic differentiation and lymphoid commitment, we established a practical protocol to generate NK cells from hPSCs without employing CD34+ cell enrichment or spin EB formation.

**Generation of PBC-iPSCs for Production of NK Cells**

To further facilitate NK cell production from hPSCs under GMP, it is helpful to start with a highly accessible hPSC source that is GMP compatible. Although hESCs, fibroblast-derived iPSCs, and umbilical cord blood CD34+ cell-derived iPSCs have been used to generate NK cells (Knorr et al., 2013; Woll et al., 2005, 2009), these hPSC sources are not ideal for GMP. Instead, PBC-iPSCs are a more accessible and practicable option from the standpoint of manufacturing because the starting material PBCs are very amenable to GMP, although the use of this hPSC source to produce NK cells remains unexplored. To study such a possibility, we first generated our own iPSC lines from PBCs (donor A) using integration-free Sendai viral vectors carrying the reprogramming factor genes. The resulting PBC-iPSC lines showed typical morphology of hPSCs (Figure 2A). They were further classified into...
PBC-iPSC lines derived from T cell or non-T cell by TCRβ and TCRγ gene clonality assays (Figures 2B and 2C). As shown in Figures 2B and 2C, a PBC-iPSC#8.3 line was identified to be derived from an αβ T cell due to the presence of rearranged TCRβ chain gene, whereas a PBC-iPSC#9 line was from a non-T cell due to the absence of both rearranged TCRβ and TCRγ chain genes.

Next, we examined whether our two-stage protocol for NK cell production is applicable to these PBC-iPSC lines. Using the non-T cell-derived PBC-iPSC#9 line, differentiated cells containing a significant CD34+ population were obtained after a 12-day co-culture with OP9 (Figure 2E). Without sorting CD34+ cells, these differentiated cells were harvested and directly co-cultured with OP9-DLL1. A small CD45+ CD56+ population appeared after the second co-culture (day 26) (Figure 2F); this population became more apparent after the fifth co-culture (day 47), which comprised 61% of the lymphoid cells (Figure 2G). Neither TCRαβ nor CD3 was expressed during the differentiation process; they were undetectable in pluripotent stem cells (Figure 2D), hematopoietic cells (Figure 2E), and lymphoid cells (Figures 2F and 2G). Moreover, there was...
no obvious CD4 or CD8 expression in the lymphoid cells (Figures 2F and 2G), confirming that our two-stage protocol could also be used for NK cell production from PBC-iPSCs. Similarly, using the T cell-derived iPSC#8.3 line, CD34+ cells were generated after a 12-day co-culture with OP9 (Figure 2I); an increasing CD45+ CD56+ population was observed with the progress of lymphoid commitment (Figures 2J and 2K), again proving the robustness of our protocol. This T cell-derived iPSC line itself expressed no TCRβ (Figure 2H), suggesting the completeness of the reprogramming process. There was no TCRβ expression in hematopoietic cells either (Figure 2I). However, PBC-iPSC#8.3 did give rise to a distinct CD3+ TCRβ+ population during lymphoid differentiation (Figures 2J and 2K), although there was no obvious CD4 or CD8 expression (Figures 2J and 2K). The re-expression of rearranged TCRγ and TCRβ chain genes in lymphoid cells differentiated from T cell-derived iPSCs is not desirable if the produced cells are to be used in an allogeneic setting. To avoid the potential GVHD caused by the re-expressed TCRβ, it is crucial to start with PBC-iPSCs derived from non-T cells rather than those from T cells.

To generate more non-T cell-derived PBC-iPSC lines, we used a different protocol to reprogram PBCs (donor B and donor C) into iPSCs, in which PBCs were first cultured in CD34+ cell-enrichment medium for 3 days and episomal reprogramming vectors were then delivered into these pre-treated PBCs via GMP-compatible nucleofection. Using this protocol, we significantly increased the probability of deriving PBC-iPSC lines from non-T cells as verified by TCRβ and TCRG gene clonality assays (Figure 2I); nine out of nine verified that PBC1-iPSC lines (donor B) were derived from non-T cells. A possible explanation for this finding is that the proliferating CD34+ cells are more susceptible to reprogramming by nucleofection than the terminally differentiated T cells. In contrast, using the reprogramming protocol with Sendai viral vectors, only five out of nine verified that PBC-iPSC lines (donor A) were from non-T cells. Several confirmed non-T cell-derived PBC-iPSC lines, including PBC-iPSC#9 (donor A), PBC1-iPSC#4 (donor B), and PBC2-iPSC#12 (donor C), were used to produce PBC-iPSC-NK cells in the following studies.

Improving Purity and Yield of NK Cells Produced from Non-T Cell-Derived PBC-iPSCs

In addition to starting with a GMP-compatible hPSC source, improving the purity and yield of NK cells produced from non-T cell-derived PBC-iPSCs will further facilitate the production of this NK cell source under GMP. To this end, we tested whether different cytokine combinations can enhance NK cell commitment. As demonstrated with PBC-iPSC#9 (donor A) (Table S1), using IL-7 together with SCF and FLT3L during lymphoid commitment brought about a purity of 61% and a yield of $0.21 \times 10^6$ CD56+ CD45+ cells per $3 \times 10^6$ PBC-iPSCs on day 40. The use of IL-15 rather than IL-7 increased the purity to 99% and the yield to $0.75 \times 10^6$, while the combined use of IL-7 and IL-15 gave a purity of 99% and a yield of $7.93 \times 10^6$ on day 40, which further increased to $15 \times 10^6$ on day 47.

Using this optimized cytokine combination, high-purity PBC-iPSC-NK cells were produced from PBC-iPSC#9 (donor A) (Figures 3A-3D). These PBC-iPSC#9-NK cells were so cytotoxic that they killed almost all OP9-DLL after the fifth co-culture (Figure 3C), which could not stain both OP9 and OP9-DLL1 (Figure S1). These cells expressed no CD3, CD19, or CD14, suggesting that they are not T cells, B cells, or monocytes (Figure 3C). Moreover, they showed typical morphology of NK cells (Figure 3B). They were a homogeneous population as demonstrated by the cell images (Figure 3B) and the scatter plot (Figures 3C and 3D). Most were CD56+ CD45+ CD3−, a typical NK cell phenotype (Figure 3D). More importantly, these cells expressed numerous receptors and surface molecules that are crucial for effector functions of NK cells, including natural cytotoxicity receptors (Nkp30, Nkp44, and Nkp46), activating receptors (NKG2D and DNAM-1), and death-inducing ligands (FasL, TRAIL) (Figure 3D). They also expressed CD16 (Figure 3D), which mediates antibody-dependent cell-mediated cytotoxicity (ADCC) of NK cells. Thus, these PBC-iPSC-NK cells express all the best-characterized activating receptors and surface molecules of NK cells that are implicated in fighting cancer. Besides activating receptors, they expressed inhibitory receptor CD94:NKG2A (Figure 3D), which may prevent over-activation of NK cells. Likewise, using PBC1-iPSC#4 (donor B), we were able to generate PBC1-iPSC#4-NK cells with a similar phenotype (Figure 3E). Hence, a large number of high-purity NK cells can be consistently produced from various PBC-iPSC lines using our optimized two-stage protocol.

Functions of PBC-iPSC-NK Cells

Secretory cytokines such as interferon-γ (IFN-γ) upon stimulation is an important functional feature of NK cells, which can be detected by an enzyme-linked immunospot (ELISPOT) assay. To investigate IFN-γ secretion, PBC-iPSC#9-NK cells were co-cultured with stimulating cancer cells. ELISPOT results (Figures 4A and 4B) showed that K562, an NK cell-sensitive leukemia cell line, was efficient in stimulating IFN-γ secretion by PBC-iPSC#9-NK cells,
Figure 2. Generation of PBC-iPSCs for Production of NK Cells

PBCs from different donors were used to generate various PBC-iPSC lines. Results were obtained using PBC-iPSC (donor A) lines (A–K) and PBC1-iPSC (donor B) lines (L).

1800 Stem Cell Reports | Vol. 9 | 1796–1812 | December 12, 2017

(legend continued on next page)
Differentiation of non-T cell-derived PBC-iPSC#9 line into NK cells. Flow cytometric analysis shows no TCR (D–K) production of NK cells from two PBC-iPSC (donor A) lines, PBC-iPSC#9 and PBC-iPSC#8.3. (D–G) Phenotypic changes during differentiation of 10^6 cryopreserved PBC-iPSC-NK cells, up to 74-fold expansion was achieved on day 9, although no further expansion was observed after extending co-culture to 14 days (Figure 5A). Interestingly, by exploiting their ADCC function, PBC-iPSC#9-NK cells were still capable of killing Raji cells (Figures 4E and 4F). As shown in Figures 4G and 4H, PBC-iPSC#9-NK cells alone were unable to kill Raji cells; neither with addition of human IgG1 or anti-CD20-mIgG1. With addition of anti-CD20-hIgG1 of various concentrations, however, distinct cytotoxicity against Raji cells appeared. Therefore, PBC-iPSC-NK cells are fully functional in terms of cytokine secretion, direct cytotoxicity, and ADCC.

**Expansion of Fresh and Cryopreserved PBC-iPSC-NK Cells**

Generating sufficient PBC-iPSC-NK cells is a prerequisite for their translation into clinical use. One possible way is to scale up the differentiation cultures, which, however, is not cost-effective. A more practical way is to expand PBC-iPSC-NK cells using feeder cells. To investigate this possibility, various numbers of PBC-iPSC#9-NK cells were co-cultured with irradiated K562-mIgG1-41BBL cells at an NK cell:feeder cell ratio of 1:10 in gas-permeable G-Rex10 flasks. Results showed that PBC-iPSC-NK cells were expandable (Figures 5A and 5B). Starting with 10^6 PBC-iPSC#9-NK cells, up to 74-fold expansion was achieved on day 9, although no further expansion was observed after extending co-culture to 14 days (Figure 5A). The expanded PBC-iPSC#9-NK cells kept their phenotype apart from the downregulation of CD16 (Figure 5C); functionally, they became more potent, as shown by higher cytotoxicity against K562 cells (Figure 5D). These findings indicate that clinical-scale production of PBC-iPSC-NK cells through expansion with feeder cells is feasible.

Shipping therapeutic cell products from a centralized manufacturing site to a clinical site for injection without compromising the product quality is crucial for the clinical success of live cell products. It is well known that transporting conventional NK cell products in cryopreserved form can significantly reduce their viability and potency (Lapteva et al., 2014), which might also be a problem for PBC-iPSC-NK cells. Indeed, current freeze/thaw procedure significantly affected viability of expanded PBC-iPSC#9-NK cells (Figure 5E), although the cytotoxicity of these cells was partially preserved (Figure 5G, expanded NK→frozen-thawed). To overcome this issue, we proposed a possible solution: at a centralized manufacturing site, PBC-iPSC-NK cells are first produced and cryopreserved (before expansion); the cryopreserved PBC-iPSC-NK cells are then shipped to a clinical site; at the clinical site, the cryopreserved PBC-iPSC-NK cells are then thawed, expanded, and injected. The feasibility of such a solution depends on the expansion capability of cryopreserved PBC-iPSC-NK cells. As shown in Figure 5F (frozen-thawed NK), the cryopreserved PBC-iPSC-NK cells remained expandable. Starting with 10^6 cryopreserved PBC-iPSC-NK cells, up to 38.5-fold expansion was achieved on day 9. Above all, these expanded cryopreserved NK cells had comparable cytotoxicity as those expanded from fresh NK cells (Figure 5G, frozen-thawed NK→expansion versus fresh NK→expansion). These results support that transporting cryopreserved pre-expansion PBC-iPSC-NK cells, followed by their expansion and injection at the clinical site, may provide a practical solution to the logistics of such cell products.

**Cytotoxicity of PBC-iPSC-NK Cells against Cancer Cells**

To evaluate the cytotoxicity of PBC-iPSC-NK cells against cancer cells, three PBC-iPSC lines, PBC-iPSC#9 (donor A), PBC1-iPSC#4 (donor B), and PBC2-iPSC#12 (donor C), were used to generate PBC-iPSC-NK cells named PBC-iPSC#9-NK cells, PBC1-iPSC#4-NK cells, and PBC2-iPSC#12-NK cells, respectively. After expansion, these PBC-iPSC-NK cells were used for cytotoxicity assay against a wide variety of cancer cell lines: K562 (chronic myelogenous leukemia), SK-OV-3 (ovary adenocarcinoma), SW480 (colorectal adenocarcinoma), HCT-8 (ileocecral colorectal adenocarcinoma), and T-24 (transitional cell carcinoma). All these cell lines were killed by PBC-iPSC-NK cells with similar efficiency as that of primary NK cells.

(A) Morphology of two PBC-iPSC (donor A) lines, PBC-iPSC#9 and PBC-iPSC#8.3.
(B and C) TCRB gene (B) and TCRg gene (C) clonality assays to detect rearranged TCRβ and TCRγ chain genes in PBC-iPSC (donor A) lines. Positive amplified product is indicated by the yellow arrow.
(D–K) Production of NK cells from two PBC-iPSC (donor A) lines, PBC-iPSC#9 and PBC-iPSC#8.3. (D–G) Phenotypic changes during differentiation of non-T cell-derived PBC-iPSC#9 line into NK cells. Flow cytometric analysis shows no TCRβ expression during differentiation. (H–K) Phenotypic changes during differentiation of T cell-derived PBC-iPSC#8.3 line into NK cells. Flow cytometric analysis shows re-expression of TCRβ during differentiation.

(L) TCRB gene and TCRG gene clonality assays to detect rearranged TCRβ and TCRγ chain genes in PBC1-iPSC (donor B) lines.
PBC-iPSC#9-NK (Donor A)

a) 5th coculture on DP8-DLL1, d47

b) Purified PBC-iPSC#9-NK

c) Flow cytometry analysis

- SSC vs FSC
- CD45 vs CD3
- CD19 vs CD14

PBC1-iPSC#4-NK (Donor B)

d) Flow cytometry analysis

- CD56+CD45+ gated

(legend on next page)
adenocarcinoma), MCF7 (breast adenocarcinoma), and SCC-25 (tongue squamous cell carcinoma). Peripheral blood NK (PB-NK) cells expanded from three different donors (donor 1, donor 2, and donor 3) were used as controls. Results showed that all tested PBC-iPSC-NK cells efficiently killed all tested cancer cell lines; cytotoxicity was observed even at very low effector to target (E:T) ratios (Figure 6). When testing against NK cell-sensitive K562 cells, cytotoxicity of PBC-iPSC-NK cells was similar to that of PB-NK cells (Figure 6A); however, against other solid tumor lines, PBC-iPSC-NK cells were consistently more efficient in killing the target cells than PB-NK cells (Figures 6B–6F).

In addition to using existing cancer cell lines, we also derived primary tumor cells from a type of solid tumor, colorectal cancer, for cytotoxicity assay. Characterization of a short-term cultured primary tumor cell line CRC7.4 is shown in Figures 6G–6K. This CRC7.4 line expressed cytokeratin (Figure 6G), but not vimentin (Figure 6H), suggesting the epithelial origin of the cancer cells. Moreover, CRC7.4 had high-level expression of CD133, a cancer stem cell (CSC) marker (Figures 6I and 6K), as well as other CSC markers such as CD44 and EpCAM (Figure 6K). There was little expression of CK20 (Figure 6J), which is usually expressed in goblet cells and enterocytes of the gastrointestinal tract. Such a phenotype indicates that the CRC7.4 line contains a high percentage of CSCs, but little differentiated cancer cells. Cytotoxicity assay showed that PBC-iPSC-NK cells were able to kill these CSC-like cancer cells at the tested E:T ratios, while the expanded PB-NK cells were inefficient at such low ratios (Figure 6L).

**KIR Typing of PBC-iPSC-NK Cells**

Signaling through inhibitory KIRs inhibits NK cell cytotoxicity. To understand the high anti-tumor efficacy of PBC-iPSC-NK cells, we compared KIR expression of PBC-iPSC-NK cells and PB-NK cells. KIR genotyping showed that donors of these different NK cells had diverse KIR gene contents (Figures 7A, 7C, 7G, and 7I; Table S2). In PB-NK cells, most KIR genes were actively expressed, as verified at the mRNA level (Figure 7B; Table S2) and the protein level (Figure 7K). In PBC-iPSC-NK cells, however, transcription of KIR genes was undetectable, except for KIR2DL4 gene, a framework KIR gene (Figures 7E, 7H, and 7J; Table S2); phenotyping further confirmed this finding, since expression of most KIRs was undetectable on the cell surface by immunostaining with various anti-KIR antibodies, although small populations of KIR2DL2/L3/S2+ cells were observed (Figures 7L, 7M, and 7N). Moreover, the NK cell expansion process did not change KIR expression in PBC-iPSC-NK cells, as demonstrated at the mRNA (Figure 7F) and protein levels (Figures 7O and 7P). These data showed that most PBC-iPSC-NK cells were negative for the widely studied inhibitory KIRs: KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL1, and KIR3DL2. Such an inhibitory KIR-negative phenotype makes PBC-iPSC-NK cells insensitive to inhibition by KIR ligands, which may account for their high anti-tumor cytotoxicity.

To understand whether the hPSC source or our differentiation protocol is responsible for the KIR-negative phenotype, we derived NK cells from two different hPSC sources: an hESC line, H1, and a fibroblast-derived iPSC line, iPSC#5.9, which was generated previously in our lab (Yang et al., 2012) (Figure S2). KIR phenotyping showed that most NK cells derived from these two hPSC sources were also KIR negative (Figure S2). These results suggest that the KIR-negative phenotype is not limited to the NK cells derived from PBC-iPSCs. Other hPSC sources can also be used to generate KIR-negative NK cells using our differentiation protocol.

**DISCUSSION**

Allogeneic NK cells are currently being used in cancer immunotherapy (Leung, 2014; Lim et al., 2015). To produce a large amount of these cells, donor-derived leukapheresis products or PBMCs are processed through either NK cell enrichment or NK cell expansion (Fujisaki et al., 2009; Koehl et al., 2013; Lapteva et al., 2014). The use of highly variable starting materials makes it difficult to consistently produce NK cell products using such manufacturing strategies. Moreover, these strategies have poor scalability due to limited availability of donor cells. The reliance on donor-derived NK cells also determines that the final products express high-level KIRs. A suitable NK cell donor has to be selected for a particular patient to achieve a KIR-HLA mismatch and thus a better clinical outcome (Benson and Caligiuri, 2014; Leung, 2014; Murphy et al., 2012; Thielens et al., 2012).
requirement of a matched donor, in this case a KIR-HLA mismatched donor, decides that such manufacturing strategies can only produce "made-to-order" NK cell products, which cannot fulfill the urgent needs of cancer patients. All these issues call for a different manufacturing approach that produces "off-the-shelf" NK cell products. To this end, we have demonstrated an overall production scheme: from blood cells to stem cells and back with less (less KIRs), to make such products. This PBC-iPSC-based manufacturing strategy is standardizable and scalable, which produces "off-the-shelf" KIR-negative NK cells that may serve a wide range of recipients disregarding their HLA genotypes in a timely manner.

To implement this production scheme under GMP, it is important to embrace GMP early on by starting with a GMP-compatible hPSC source. Among current hPSC sources, hESCs are a safe option, but their derivations are ethically controversial and their applications are strictly allogeneic. In contrast, iPSCs have no ethical issue and they can be applied in both autologous and allogeneic settings. Various starting cells have been used to derive iPSC lines (Gonzalez et al., 2011). The choice of starting cells affects not only the efficiency and kinetics of reprogramming, but also practicality in deriving GMP-grade iPSCs. Although skin fibroblasts are most commonly used to derive iPSC lines, they are not ideal for GMP. Deriving skin fibroblasts requires collection of skin samples through an invasive punch biopsy and a time-consuming process to grow fibroblasts from skin sample (it takes up to 3 weeks), and doing all these under GMP is a daunting task. Unlike deriving skin fibroblasts, obtaining PBCs is much simpler: it only requires blood sample collection through a routine blood withdrawal and a simple isolation of mononuclear cells using Ficoll-Paque, both of which are GMP ready. Thus, we used iPSCs to derive PBC-iPSC lines for NK cell production. It is noteworthy that not all PBC-iPSC lines are created equal in terms of NK cell production. Our findings suggest that while using a T cell-derived PBC-iPSC line, the rearranged TCR genes will re-express, which is not desirable due to the risk of GVHD in allogeneic application. To avoid such a consequence, one should only use non-T cell-derived PBC-iPSC lines. For this reason, we also established a reprogramming protocol using GMP-compatible nucleofection to derive PBC-iPSC lines of non-T cell-origin. With these verified non-T cell-derived lines, we successfully demonstrated the production of NK cells from PBC-iPSCs.

Inducing hematopoietic differentiation of hPSCs is a crucial first step for generating NK cells from hPSCs. One approach is to co-culture hPSCs with bone marrow stromal cells (e.g., S17 and M2-10B4) to obtain CD34+ hematopoietic precursors (Knorr et al., 2013; Woll et al., 2005, 2009). However, it requires co-culture for as long as 21 days and subsequent sorting of CD34+ cells before differentiation into NK cells. This cell-sorting step not only complicates the protocol, but also reduces yield of NK cells because it excludes many other hematopoietic progenitors that are also competent for differentiation into NK cells. Another approach is to form EBs (Tabatabaei-Zavareh et al., 2007) and recently spin EBs (Knorr et al., 2013). Spin EB formation requires a prior time-consuming adaptation of hPSCs to TrypLE digestion for at least ten passages on mouse embryonic fibroblasts, which may not be easy for many hPSC lines. To form spin EBs, TrypLE-adapted hPSCs are seeded onto 96-well plates at a density of 3,000 cells per well and spun down. This is followed by harvesting and seeding spin EBs at a density of six spin EBs per well on 24-well plates for further NK cell differentiation. Technically, spin EB approach is labor-intensive, skill-demanding, and difficult for large-scale production. Inherently, the hematopoietic progenitors generated via spin EB formation are variable and inconsistent, which may result in high variation in later NK cell development. It has been demonstrated that the adaptation of hPSCs to TrypLE digestion is not necessary for hPSC aggregation, since the inclusion of ROCK inhibitor in the medium is sufficient for any hPSCs to form aggregates in U-bottomed 96-well plates following TrypLE dissociation (Lancaster et al., 2013; Nakano et al., 2012). However, it remains to be tested whether the use of ROCK inhibitor will affect the differentiation of hPSCs into NK cells. To develop a practical protocol, we revisited the co-culture approach using OP9, a classical M-CSF-deficient stromal cell line, which has been reliably used to generate dendritic cells from hPSCs in our previous studies (Zeng et al., 2012, 2015; Zeng and Wang, 2014).

**Figure 4. Functions of PBC-iPSC-NK Cells**
(A and B) IFN-γ secretion by PBC-iPSC#9-NK cells (donor A) upon stimulation with K562 and Raji cells as detected by ELISPOT assay. ELISPOT images (A) and spot counting (mean ± SD, n = 3) (B) are shown.
(C and D) GrB secretion by PBC-iPSC#9-NK cells upon stimulation with K562 cells as detected by ELISPOT assay. ELISPOT images (C) and spot counting (mean ± SD, n = 3) (D) are shown.
(E and F) Cytotoxicity of PBC-iPSC#9-NK cells against K562 and Raji cells as measured by flow cytometry. A representative flow cytometric analysis (E) and a result summary (F) are shown.
(G and H) ADCC of PBC-iPSC#9-NK cells against Raji cells in the presence of anti-CD20 humanized antibody as measured by flow cytometry. A representative flow cytometric analysis (G) and a result summary (H) are shown. These data are representative of three independent experiments.
By co-culturing with OP9, efficient hematopoietic differentiations of hESCs and PBC-iPSCs have been consistently achieved within 12 days, which is significantly shorter than using other stromal cell lines. Without sorting CD34+ cells, harvested hematopoietic cells can be directly used for further differentiation. Thus, using OP9 to induce hematopoietic differentiation can significantly simplify the manufacturing process.

Promoting lymphoid commitment of hematopoietic progenitors by further co-culturing them with stromal cell lines is the second step for generating NK cells from hPSCs. Although stromal cell lines, such as MS-5 and

Figure 5. Expansion of Fresh and Cryopreserved PBC-iPSC-NK Cells
(A and B) Expansion of fresh PBC-iPSC#9-NK cells by K562-mbIL15-41BBL in G-Rex10 starting with different NK cell numbers. Absolute numbers of NK cells during a 14-day expansion (A) and fold changes after expansion (B) are shown.
(C and D) Phenotype (C) and cytotoxicity against K562 (D) of fresh PBC-iPSC#9-NK cells after expansion as measured by flow cytometry.
(E) Viability of expanded PBC-iPSC#9-NK cells after freeze/thaw procedure.
(F) Expansion of cryopreserved PBC-iPSC#9-NK cells.
(G) Cytotoxicity of cryopreserved PBC-iPSC#9-NK cells against K562 after expansion. These data are representative of three independent experiments.
AFT024, have been used, the resulting cells were heterogeneous populations containing both CD56+ and CD56− cells (Vodyanik et al., 2005; Woll et al., 2005, 2009). Improved NK development was observed using a stromal cell line EL08-D12 (McCullar et al., 2008); however, its efficacy was only demonstrated with sorted CD34+ cells or spin EBs (Knorr et al., 2013; Woll et al., 2009). Knorr et al. (2013) also demonstrated that hPSC-derived stromal cells support NK cell development from hematopoietic progenitor cells. However, in terms of robustness, hPSC-derived stromal cells were even less efficient than the EL08-D12 cells; the former could only produce NK cells with 76.4% purity from UCB CD34+ cells, while the latter produced 96.7% (Knorr et al., 2013). To provide a robust microenvironment for NK cell development, we used OP9-DLL1, a modified OP9 cell line expressing Notch ligand DLL1, together with an NK cell-promoting cytokine cocktail (SCF, FLT3L, IL-7, and IL-15). This is because activation of Notch signaling pathway is vital for development of innate lymphoid cells (De Obaldia and Bhandoola, 2015). Notch ligand DLL1 suppresses B cell development and promotes NK cell development from human cord blood CD34+ cells (Jaleco et al., 2001). Moreover, DLL1 is able to augment the proliferation of primitive hematopoietic progenitor in vitro (Karanu et al., 2001), thus providing a potential benefit to increase the yield of NK cells from hPSCs. In this study, we have demonstrated that, using OP9-DLL1 as feeders, heterogeneous hematopoietic cells harvested from PBC-iPSC/OP9 co-cultures can be directly seeded to generate NK cells. The end products were homogeneous CD56+ CD45+ lymphoid populations.

Figure 6. Cytotoxicity of PBC-iPSC-NK Cells against Cancer Cells

Three different sources of PBC-iPSC-NK cells, including PBC-iPSC#9-NK cells (donor A), PBC1-iPSC#4-NK cells (donor B), and PBC2-iPSC#12-NK cells (donor C), were used for cytotoxicity assay against a wide variety of cancer cell lines: K562 (A), SK-OV-3 (B), SW480 (C), HCT-8 (D), MCF7 (E), and SCC-25 (F). PB-NK cells expanded from three different donors (donor 1, donor 2, and donor 3) were used as controls. (G–I) A short-term cultured primary tumor cell line CRC7.4 was derived from a colorectal cancer sample and characterized by immunostaining (G–J) and flow cytometry (K). These primary tumor cells were then use as target cells to evaluate the cytotoxicity of PBC-iPSC#9-NK cells (L). PB-NK cells expanded from three donors (donor 4, donor 5, and donor 6) were used as controls. Student’s paired two-tailed t test was used to analyze the difference between the specific lysis of target cells by PBC-iPSC-NK cells and that by PB-NK cells. The p values were calculated for each type of target cell and a p value less than 0.05 was considered to be statistically significant. These data are representative of three independent experiments.
(legend on next page)
(2) our differentiation approach, which excludes cell sorting, EB formation, and spin EB formation in the process, and includes the use of OP9-DLL1 cells to provide active Notch signaling to induce lymphoid commitment, is more robust and practical; (3) the produced PBC-iPSC-NK cells are a high-purity and functional population, obviating the need for T and B cell depletion or NK cell enrichment; (4) both fresh and cryopreserved PBC-iPSC-NK cells can be expanded in a short period of time, which eases the logistics of manufacturing and transporting of these products; (5) further functional maturation and clinical-scale production can be achieved by cell expansion (starting with $3 \times 10^6$ PBC-iPSCs, $15 \times 10^6$ NK cells can be generated in 47 days; using feeder cells, these NK cells can be further expanded by 74-fold in 9–14 days; thus, by combining the differentiation and expansion processes, a total number of $1.1 \times 10^9$ potent NK cells can be produced to meet the clinical requirements not only in quantity but also in quality); and (6) most PBC-iPSC-NK cells are KIR negative, which may serve as a universal “off-the-shelf” cell source for various recipients. Interestingly, starting with an autologous PBC-iPSC line, it is possible to generate autologous KIR-negative NK cell source to be used under an autologous setting without worrying about the inhibition imposed by self HLA molecules. With a reduced risk of immune rejection, these autologous PBC-iPSC-NK cells may survive longer and thus provide a prolonged anti-tumor activity. However, it is noteworthy that the presented system relies on two stromal cell lines to differentiate hPSCs into NK cells that possess the above-mentioned unique product features. These cell lines could be the sources of cost and logistic problems during manufacturing. To further simplify the production process, the development of chemically defined coating matrix proteins that competently replace these cell lines could be certainly helpful.

In summary, we have established a “from blood cells to stem cells and back with less” strategy to mass-produce “off-the-shelf” NK cells from PBC-iPSCs for a wide range of recipients.

**EXPERIMENTAL PROCEDURES**

**Generation of NK Cells from hPSCs**

To generate NK cells from hPSCs, we established a two-stage protocol. In the first stage, OP9 cells were seeded on 0.1% gelatin (STEMCELL Technologies)-coated T75 flasks. Upon confluence, the cultures were fed by changing half of the medium and overgrown for 4–6 days. A total of $1–1.5 \times 10^6$ hPSCs were then seeded and differentiated on the overgrown OP9 cells in alpha minimum essential medium (α-MEM) supplemented with 20% fetal bovine serum (FBS) for 12 days. The hPSC/OP9 co-cultures were fed every 4 days by changing half of the medium. In the second stage, the differentiated cells were harvested from the hPSC/OP9 co-cultures using 1 ng/mL Collagenase Type IV (STEMCELL Technologies) and TrypLE Express (Thermo Fisher Scientific). OP9 cells were removed by plastic adherence for 45 min and the cell clumps were further removed by 100 μm cell strainers (BD Biosciences). The remaining non-adenherent cells were then co-cultured with OP9-DLL1 cells grown on T75 flasks using α-MEM containing 20% FBS, 10 ng/mL SCF (PeproTech), 5 ng/mL FLT3L (PeproTech) together with 5 ng/mL IL-7 (PeproTech), and/or 10 ng/mL IL-15 (PeproTech) for 7 days. Hereafter, the differentiated cells were harvested using Versene (Thermo Fisher Scientific) and co-cultured on new OP9-DLL1 cells grown on six-well plates on a weekly basis for another 3–4 weeks. After the final co-culture, the harvested cells were further purified by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare Life Sciences) followed by overnight culture.

**Generation of PBC-iPSCs**

To generate iPSCs from PBCs, two different reprogramming protocols were established: one was using Sendai viral vectors (Thermo Fisher Scientific), while the other was using episomal reprogramming vectors (Thermo Fisher Scientific) as described in the Supplemental Experimental Procedures.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures, two figures, and three figures and can be found with this article online at https://doi.org/10.1016/j.stemcr.2017.10.020.

**AUTHOR CONTRIBUTIONS**

J.Z., conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing. S.Y.T., conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing. L.L.T., conception and design, collection and/or assembly of data. S.W., conception and design, data analysis and interpretation, manuscript writing, final approval of manuscript.

**ACKNOWLEDGMENTS**

This work was supported by the Singapore Ministry of Health’s National Medical Research Council (NMRC/CIRG/1367/2013; 10.020.

Figure 7. KIR Typing of PBC-iPSC-NK Cells

(A–J) KIR genotyping and mRNA expression profiling. Electrophoresis of PCR products of genomic DNA shows KIR gene content and endogenous β-actin gene of a PB-NK donor (donor 4) (A) and three PBC donors for PBC-iPSC#9 (donor A) (C), PBC1-iPSC#4 (donor B) (G), and PBC2-iPSC#12 (donor C) (I). Electrophoresis of PCR products of cDNA shows mRNA expression of KIR genes and endogenous β-actin gene in PB-NK cells (B), PBC-iPSC#9 cells (D), PBC-iPSC#9-NK cells (E), post-expansion PBC-iPSC#9-NK cells (F), PBC1-iPSC#4-NK cells (H), and PBC2-iPSC#12-NK cells (J).

(K–P) KIR phenotyping of different NK cells by flow cytometry.
REFERENCES

Benson, D.M., Jr., and Caligiuri, M.A. (2014). Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunol. Res. 2, 99–104.

Benson, D.M., Jr., Hofmeister, C.C., Padmanabhan, S., Suvannasanka, A., Jagannath, S., Abonour, R., Bakam, C., Andre, P., Efebera, Y., Tiollier, J., et al. (2012). A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120, 4324–4333.

Benson, D.M., Jr., Cohen, A.D., Jagannath, S., Munshi, N.C., Spitzer, G., Hofmeister, C.C., Efebera, Y.A., Andre, P., Zerbib, R., and Caligiuri, M.A. (2015). A phase 1 trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin. Cancer Res 21, 4055–4061.

Colucci, F., Caligiuri, M.A., and Di Santo, J.P. (2003). What does it take to make a natural killer? Nat. Rev. Immunol. 3, 413–425.

De Obaldia, M.E., and Bhandoola, A. (2015). Transcriptional regulation of innate and adaptive lymphocyte lineages. Annu. Rev. Immunol. 33, 607–642.

Domogala, A., Madrigal, J.A., and Saudemont, A. (2015). Natural killer cell immunotherapy: from bench to bedside. Front. Immunol. 6, 264.

Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W.H., and Campana, D. (2009). Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 69, 4010–4017.

Gonzalez, F., Boue, S., and Izpisua Belmonte, J.C. (2011). Methods for making induced pluripotent stem cells: reprogramming a la carte. Nat. Rev. Genet. 12, 231–242.

Jaleco, A.C., Neves, H., Hooijberg, E., Gameiro, P., Clode, N., Haury, M., Henrique, D., and Parreira, L. (2001). Differential effects of Notch ligands Delta-1 and Jagged-1 in human lymphoid differentiation. J. Exp. Med. 194, 991–1002.

Karanu, F.N., Murdoch, B., Miyabayashi, T., Ohno, M., Koremoto, M., Gallacher, L., Wu, D., Itoh, A., Sakano, S., and Bhatia, M. (2001). Human homologues of Delta-1 and Delta-4 function as mitogenic regulators of primitive human hematopoietic cells. Blood 97, 1960–1967.

Knorr, D., Ni, Z., Hermanson, D., Hexum, M.K., Bendzick, L., Cooper, L.J., Lee, D.A., and Kaufman, D.S. (2013). Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl. Med. 2, 274–283.

Koehl, U., Brehm, C., Huencke, S., Zimmermann, S.Y., Kloess, S., Bremm, M., Ullrich, E., Soerenson, J., Quaiser, A., Erben, S., et al. (2013). Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front. Oncol. 3, 118.

Lancaster, M.A., Renner, M., Martin, C.A., Wenzel, D., Bicknell, L.S., Hurles, M.E., Homfray, T., Penninger, J.M., Jackson, A.P., and Knoblich, J.A. (2013). Cerebral organoids model human brain development and microcephaly. Nature 501, 373–379.

Lapteva, N., Szmania, S.M., van Rhee, F., and Rooney, C.M. (2014). Clinical grade purification and expansion of natural killer cells. Crit. Rev. Oncog. 19, 121–132.

Leung, W. (2014). Infusions of allogeneic natural killer cells as cancer therapy. Clin. Cancer Res 20, 3390–3400.

Lim, O., Jung, M.Y., Hwang, Y.K., and Shin, E.C. (2015). Present and future of allogeneic natural killer cell therapy. Front. Immunol. 6, 286.

McCullar, V., Oostendorp, R., Panoskaltis-Mortari, A., Yun, G., Lutz, C.T., Wagner, J.E., and Miller, J.S. (2008). Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. Exp. Hematol. 36, 598–608.

Miller, J.S. (2013). Therapeutic applications: natural killer cells in the clinic. Hematol. Am. Soc. Hematol. Educ. Program 2013, 247–253.

Moretta, L., Pietra, G., Montaldo, E., Vacca, P., Pende, D., Falco, M., Del Zotto, G., Locatelli, F., Moretta, A., and Mingari, M.C. (2014). Human NK cells: from surface receptors to the therapy of leukemias and solid tumors. Front. Immunol. 5, 87.

Murphy, W.J., Parham, P., and Miller, J.S. (2012). NK cells – from bench to clinic. Biol. Blood Marrow Transpl. 18, 52–57.

Nakano, T., Ando, S., Takata, N., Kawada, M., Muguruma, K., Sekiguchi, K., Saito, K., Yonemura, S., Eiraku, M., and Sasai, Y. (2012). Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell 10, 771–785.

Parham, P. (2005). MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 5, 201–214.

Tabatabaei-Zavareh, N., Vlasova, A., Greenwood, C.P., and Takei, F. (2007). Characterization of developmental pathway of natural killer cells from embryonic stem cells in vitro. PLoS One 2, e232.

Thielen, A., Vivier, E., and Romagne, F. (2012). NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr. Opin. Immunol. 24, 239–245.

Vey, N., Bourhis, J.H., Boissel, N., Bordessoulle, D., Prebet, T., Charbonnier, A., Etienne, A., Andre, P., Romagne, F., Benson, D., et al. (2012). A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 120, 4317–4323.

Vodyanik, M.A., Bork, J.A., Thomson, J.A., and Slukvin, I.I. (2005). Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood 105, 617–626.

Woll, P.S., Martin, C.H., Miller, J.S., and Kaufman, D.S. (2005). Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J. Immunol. 175, 5095–5103.

Woll, P.S., Grzywacz, B., Tian, X., Marcus, R.K., Knorr, D.A., Vermeer, M.R., and Kaufman, D.S. (2009). Human embryonic stem cells differentiate into a homogeneous population of
natural killer cells with potent in vivo antitumor activity. Blood 113, 6094–6101.
Yang, J., Lam, D.H., Goh, S.S., Lee, E.X., Zhao, Y., Tay, F.C., Chen, C., Du, S., Balasundaram, G., Shahbazi, M., et al. (2012). Tumor tropism of intravenously injected human-induced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model. Stem Cells 30, 1021–1029.
Zeng, J., Shahbazi, M., Wu, C., Toh, H.C., and Wang, S. (2012). Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression. J. Immunol. 188, 4297–4304.
Zeng, J., and Wang, S. (2014). Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response. Stem Cells Transl. Med. 3, 69–80.
Zeng, J., Wu, C., and Wang, S. (2015). Antigenically modified human pluripotent stem cells generate antigen-presenting dendritic cells. Sci. Rep. 5, 15262.